Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer

Everolimus (EVE) in combination with hormone therapy (HT) has been shown to improve progression free survival for advanced HR+/HER2- breast cancer (BC). The double blind randomized UNIRAD trial aimed to investigate the benefit of adjuvant EVE in combination with standard adjuvant HT versus HT alone for women with high-risk HR+/HER2- early BC. Women with high-risk HR+/HER2- early BC (≥4 N+ or 1-3 N+ and EPclin score ≥ 3.3) who had completed...